77 search results for lung cancer
Treatment by Cancer Type
Treatment by Cancer Type, Care Specific Populations All Breast Cancer Resources All Lung Cancer Resources, Version: 2022 Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer, Version: 2024 Small Cell Lung Cancer, Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/treatment-by-cancer-typeDetection, Prevention, and Risk Reduction
Care Specific Populations All Breast Cancer Resources All Lung Cancer Resources, Version: 2022 Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer, Version: 2024 Small Cell Lung Cancer, Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/detection-prevention-and-risk-reductionSupportive Care
Care Specific Populations All Breast Cancer Resources All Lung Cancer Resources, Version: 2022 Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer, Version: 2024 Small Cell Lung Cancer, Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/supportive-careSpecific Populations
Care Specific Populations All Breast Cancer Resources All Lung Cancer Resources, Version: 2022 Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer, Version: 2024 Small Cell Lung Cancer, Version: 2025 Lung Cancer Screening
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/specific-populationsTransparency Process
Adult Cancer Pain Panel Version: 2.2024 ( Adult Cancer, ( Adult Cancer Pain ) Date: 2023-09-28 Transparency Panel Disclosures/Attendance Version: 1.2023 ( Adult Cancer Pain ) Date: 2022-09-12 Transparency Panel, Bladder/Penile Cancers Panel Version: 1.2025 ( Penile Cancer ) Date: 2024-08-13 Transparency Panel Disclosures/Attendance Version
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsNCCN Guidelines for Patients with Permission Email
Myeloid Leukemia Colon Cancer Esophageal Cancer Head and Neck Cancers: Nasopharyngeal Cancer Oral Cancers Oropharyngeal Cancer Hepatobiliary Cancers: Liver Cancer Gallbladder and Bile Duct Cancers Hodgkin Lymphoma Kidney Cancer Lung Cancer: Early and Locally Advanced Metastatic Malignant, e a a n d Vomiting Cancer Screening Lung Cancer Screening Age-Related Adolescents and Yo u n g, Invasive Metastatic Colon Cancer Kidney Cancer Lung Cancer: Early and Locally Advanced
https://www.nccn.org/docs/default-source/patient-resources/nccn-guidelines-for-patients-with-permission-email.pdf?sfvrsn=94769ebd_2About the NCCN Guidelines for Patients
than 25 years, the National Comprehensive Cancer Network® (NCCN®) has developed resources to improve the quality of cancer care. These resources include the award-winning NCCN Guidelines for Patients, discuss options with their cancer care team. This library of free resources is made possible through, for their ability to empower people with cancer and caregivers. Recent Awards, Annual Communicator Award of Distinction for the NCCN Guidelines for Patients: Kidney Cancer
https://www.nccn.org/patientresources/patient-resources/about-the-nccn-patient-guidelinesGuidelines for Patients
Version: 2023 Lung Cancer Screening, : 2022 Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer, Version: 2024 Small Cell Lung Cancer, Cancer Version: 2023 Adrenal Tumors
https://www.nccn.org/guidelines/patientsYoung Investigator Awards
Cancers Zachary Frosch, MD, MSHP, Fox Chase Cancer Center Developing Patient-Centered, Institute Intervention Mapping to Improve Lung Cancer Screening Among Black Veterans Ravi, in Patients with Small Cell Lung Cancer Shivan Mehta, MD, MBA, MSHP, Assistant Professor, . News Details The National Comprehensive Cancer Network® (NCCN, NCCN Member Institutions represent tomorrow’s leaders for advancing cancer care. The NCCN Oncology
https://www.nccn.org/education-research/nccn-oncology-research-program/young-investigator-awardsYoung Investigator Awards
and Esophagogastric Cancers Zachary Frosch, MD, MSHP, Fox Chase Cancer Center Developing Patient-Centered, to Improve Lung Cancer Screening Among Black Veterans Ravi Parikh, MD, MPP, The Abramson Cancer, with Small Cell Lung Cancer Shivan Mehta, MD, MBA, MSHP, Assistant Professor of Medicine, The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® each, tomorrow’s leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) manages
https://www.nccn.org/patientresources/patient-resources/nccn-foundation/young-investigator-awardsTreatment by Cancer Type
Treatment by Cancer Type, Version: 4.2024 Non-Small Cell Lung Cancer, Small Cell Lung Cancer Version: 4.2025, Clinical Oncology International Professionals Treatment by Cancer Type, Version: 2.2025 Basal Cell Skin Cancer, Version: 1.2025 Biliary Tract Cancers
https://www.nccn.org/guidelines/category_1PAS Policy Report Precision Medicine Final
for the appropriate biomarker tests. Lung and other cancers require significant surgical intervention, and Implications for Quality, Accessible, and Equitable Cancer Care In recent years, targeted medicines have offered dramatic advancements in cancer care outcomes across a wide variety of cancer types. However, as cancer care becomes increasingly personalized, access to biomarker testing and targeted, , the National Comprehensive Cancer Network (NCCN ® ) conducted a patient advocacy scan
https://www.nccn.org/docs/default-source/oncology-policy-program/pas-policy-report-precision-medicine-final.pdf?sfvrsn=468e4a2b_1Submission Request Form
Tract Cancers - 6.2024 Bladder Cancer - 6.2024 Bone Cancer - 1.2025 Breast Cancer - 6.2024 Breast, - 2.2025 Castleman Disease - 1.2025 Central Nervous System Cancers - 4.2024 Cervical Cancer - 1.2025, - 3.2025 Lung Cancer Screening - 1.2025 Management of Immunotherapy-Related Toxicities - 1.2025, - 4.2024 Non-Small Cell Lung Cancer - 3.2025 Occult Primary - 2.2025 Older Adult Oncology - 1.2025, Detection - 2.2024 Rectal Cancer - 5.2024 Small Bowel Adenocarcinoma - 2.2025 Small Cell Lung
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formAsia
at NCCN.org), as well as Chinese translations. Visit nccnchina.org.cn Chinese Gynecologic Cancer Society (CGCS): In collaboration with the Chinese Gynecologic Cancer Society (CGCS) and Shanghai Yanxin Cultural Firm, NCCN will work with the leading cancer care experts in China to translate and adapt NCCN Guidelines for Gynecologic Cancers, including cervical Cancer, Ovarian Cancer, Uterine Neoplasms, Gestational Trophoblastic Neoplasia, and Vulvar Cancer. China Editions of NCCN Guidelines
https://www.nccn.org/global/global-program/asiaWebinars for Patients
to view afterward. Upcoming Live Webinars Small Cell Lung Cancer - Monday, April 21, 2025 Register Now Recorded Webinars Why Should I Consider a Clinical Trial? (2025) Non-Small Cell Lung Cancer (NSCLC, resources, breast cancer, lung cancer, recorded webinars, recorded patient webinar, myeloma, lymphoma, NCCN provides free webinars for people affected by cancer and caregivers. These live, Neoplasms (MPN) (2024) Breast Cancer Screening (2024) Advanced and Metastatic Bladder Cancer (2024
https://www.nccn.org/patientresources/patient-resources/patient-webinarsNCCN Continuing Education Portal
Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer 1.00 AAPA, - Metastatic Castration-Resistant Prostate Cancer: Systemic Therapy Updates 1.00 AAPA Category 1 CME, $0.00 Patient Management Simulator: Treatment Recommendations for Kidney Cancer, $0.00 Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent, : 215.690.0280Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved Powered by the EthosCE
https://www.nccn.org/education-research/continuing-education-(ce)/continuing-educationNCCN History
for the treatment of cancer and perform outcomes research – and so the NCCN was born. With 13 original NCCN, to people with cancer across the country. NCCN became a developer and promoter of national programs, , and patient care. Now an alliance of 33 of the leading cancer centers, NCCN develops and communicates, for the treatment of cancer and perform outcomes research 1995 – Bruce R. Ross leads NCCN as Chief, for the following disease types: Acute Leukemia and Breast, Colon, Lung, Ovarian, Pediatric
https://www.nccn.org/home/about/nccn-historyThe Impact of Policy Regulation on Guideline-Concordant Care Globally Summary Article
specific cancers. One significant step to reduce cancer incidence is to eliminate tobacco usage, based on the WHO EML for cancers with the highest incidence in LLMICs. These cancers include lung, of patients with cancer lack access to essential medicines, crucial health infrastructure, and coordinated multidisciplinary cancer care. One path forward is an active effort from policymakers, cancer types and standardization of care through clinical practice guidelines in oncology. Moreover
https://www.nccn.org/docs/default-source/global/the-impact-of-policy-regulation-on-guideline-concordant-care-globally-summary-article.pdf?sfvrsn=b36df21a_3Chemotherapy Order Templates Reviewer Acknowledgement
Fred & Pamela Buffett Cancer Center Biliary Tract Cancers, Carbone Cancer Center Central Nervous System Cancers Emily Armgardt, Fox Chase Cancer Center Non-Small Cell Lung Cancer Sally, UC San Diego Moores Cancer Center Pediatric Central Nervous System Cancers, of Pennsylvania Small Cell Lung Cancer Sally Barbour, PharmD
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementAdvocacy December Toolkit_2021
Cholangiocarcinoma Foundation 4 Fight Colorectal Cancer 6 GO2 Foundation for Lung Cancer 7 ICAN, NCCN Digital Booklet of Patient Advocacy Resources National Comprehensive Cancer Network, , A c c e s s i b l e , a n d Equitable Cancer Care The NCCN Digital Resource Booklet includes, to precision medicine and address related needs for people with cancer. This Booklet was developed in conjunction with The National Comprehensive Cancer Network’s ® (NCCN ® ) Virtual Patient
https://www.nccn.org/docs/default-source/oncology-policy-program/advocacy-december-toolkit_2021.pdf?sfvrsn=4c2c60da_1